Implantable Ultrasound‐Powered MXene/PVA Hydrogel‐Based Generator for Treatment of Glioblastoma

Abstract

Glioblastoma (GBM) is a lethal disease with a poor prognosis due to its strong infiltration, which makes it difficult to remove completely. In this study, an implantable, modulus‐tunable, and ultrasound‐powered MXene/PVA hydrogel‐based tumor treatment device (UP‐MPH‐TTD), which generates specific electromagnetic alternating fields that disrupt the mitosis of cancer cells without adversely affecting normal neurons is developed. The MXene/PVA hydrogel is used to form a tumor treatment field due to its high biocompatibility, excellent flexibility, and high conductivity, which improves ultrasonic electrical conversion efficiency and significantly reduces the size of the equipment. The implantable UP‐MPH‐TTD is wirelessly ultrasound‐powered, small‐sized, lightweight, and simply structured, significantly boosting therapeutic efficiency and reducing restrictions on patient movement. In vitro and in vivo experiments confirmed the device's therapeutic effect, demonstrating a ≈92% inhibition rate in the growth of clinical tumor cells and a 73% reduction in tumor area in tumor‐bearing mice. The promising results indicate the broad application potential of the device in the treatment and prognostic improvement of GBM.